GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) » Definitions » Tax Rate %

ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Tax Rate % : 0.00% (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is ImmuneOnco Biopharmaceuticals (Shanghai) Tax Rate %?

Tax Rate % is calculated as Tax Expense divided by its Pre-Tax Income. ImmuneOnco Biopharmaceuticals (Shanghai)'s Tax Expense for the six months ended in Jun. 2024 was HK$0.00 Mil. ImmuneOnco Biopharmaceuticals (Shanghai)'s Pre-Tax Income for the six months ended in Jun. 2024 was HK$-178.45 Mil. Therefore, ImmuneOnco Biopharmaceuticals (Shanghai)'s Tax Rate % for the quarter that ended in Jun. 2024 was 0.00%.

ImmuneOnco Biopharmaceuticals (Shanghai) Tax Rate % Historical Data

The historical data trend for ImmuneOnco Biopharmaceuticals (Shanghai)'s Tax Rate % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmuneOnco Biopharmaceuticals (Shanghai) Tax Rate % Chart

ImmuneOnco Biopharmaceuticals (Shanghai) Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Tax Rate %
- - - -

ImmuneOnco Biopharmaceuticals (Shanghai) Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Tax Rate % Get a 7-Day Free Trial - - - - -

ImmuneOnco Biopharmaceuticals (Shanghai) Tax Rate % Calculation

Tax Rate % is the ratio of tax expense divided by pretax income, usually presented in percent.

ImmuneOnco Biopharmaceuticals (Shanghai)'s Tax Rate % for the fiscal year that ended in Dec. 2023 is calculated as

Tax Rate %=Tax Expense (A: Dec. 2023 )/Pre-Tax Income (A: Dec. 2023 )
=0/-415.044
=0.00 %

ImmuneOnco Biopharmaceuticals (Shanghai)'s Tax Rate % for the quarter that ended in Jun. 2024 is calculated as

Tax Rate %=Tax Expense (Q: Jun. 2024 )/Pre-Tax Income (Q: Jun. 2024 )
=0/-178.448
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ImmuneOnco Biopharmaceuticals (Shanghai) Tax Rate % Related Terms

Thank you for viewing the detailed overview of ImmuneOnco Biopharmaceuticals (Shanghai)'s Tax Rate % provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmuneOnco Biopharmaceuticals (Shanghai) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) » Definitions » Tax Rate %
Comparable Companies
HKSE:06996 HKSE:06978 HKSE:02181 HKSE:01521 HKSE:02509 HKSE:02487 HKSE:02137 HKSE:02566 HKSE:02563 HKSE:01167 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
R9Z:Germany
Address
1000 Zhangheng Road, Unit 15, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai, CHN
Website
http://cn.immuneonco.com
ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. It is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. It has developed a rich pipeline of 14 drug candidates with eight ongoing clinical programs, featured by a comprehensive innate-immunity-based asset portfolio. Its pipeline reflects its extensive understanding of the frontiers of cancer biology and immunology and its expertise in turning scientific research into drug candidates.
Executives
Tian Wenzhi 2501 Other
Yu Xiaoyong 2201 Interest of corporation controlled by you
Shang Hai Zhang Ke Ling Yi Sheng Fan Chuang Ye Tou Zi Zhong Xin You Xian He Huo 2101 Beneficial owner
Shang Hai Zhang Jiang Ke Ji Chuang Ye Tou Zi You Xian Gong Si 2101 Beneficial owner
Greater Bay Area Homeland Investments Limited 2201 Interest of corporation controlled by you
Jia Xing Han Ning Qi Ye Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Halo Biomedical Lp 2201 Interest of corporation controlled by you
Halo Biomedical Investment Ii Limited 2101 Beneficial owner
Halo Biomedical Investment I Limited 2201 Interest of corporation controlled by you
Lav Immon Hong Kong Limited 2101 Beneficial owner
Ho Yao
Greater Bay Area Homeland Development Fund (gp) Limited 2201 Interest of corporation controlled by you
Gba Fund Investment Limited 2101 Beneficial owner
Lav Immuneonco Hong Kong Limited 2101 Beneficial owner
Lav Gp V, L.p. 2201 Interest of corporation controlled by you

ImmuneOnco Biopharmaceuticals (Shanghai) Headlines

No Headlines